[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-metastases-from-solid-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-metastases-from-solid-tumors":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,90,116,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100526603","phase-1-a-first-in-human-phase-1-study-evaluating-oral-tacc3-ppi-inhibitor-ao-252-in-advanced-solid-tumors-with-or-without-brain-metastases-100526603",false,"NCT06136884","A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases","A Phase 1, Open-Label, Dose-escalation and Dose-Expansion Study Evaluating AO-252, a Protein-Protein Interaction Inhibitor of TACC3, in Patients With Advanced Solid Tumors With or Without Brain Metastases","Inclusion Criteria:\n\n1. Adults ≥ 18 years of age.\n2. Patient has histologically or cytologically confirmed metastatic or locally advanced unresectable solid tumors with TP53 mutation\u002Floss and with\u002Fwithout brain metastasis. Patients must have relapsed\u002Fbe refractory to at least 1 line of systemic therapy in the metastatic setting (excluding melanoma).\n3. Prostate cancer:\n\n   1. mCRPC with histologic confirmation of adenocarcinoma. mCRPC with neuroendocrine features or mixed histology are excluded\n   2. Patients will be enrolled irrespective of the TP53 status\n   3. Participant must have prostate specific antigen (PSA) of ≥ 2 ng\u002FmL\n   4. Is surgically or medically castrated, with testosterone levels of less than 50 ng\u002FdL\n   5. Patients who progressed on at least 1 prior novel androgen receptor AR-targeted therapy (that is, abiraterone acetate, apalutamide, enzalutamide, darolutamide), and or at least 1 prior systemic chemotherapy (e.g., docetaxel)\n4. Solid tumors with brain metastasis:\n\n   1. Histologically or cytologically confirmed metastatic or locally advanced unresectable solid tumors excluding melanoma with TP53 mutation\u002Floss and tumor must have relapsed\u002Fbe refractory to at least 1 line of systemic therapy. Untreated brain metastases not requiring immediate local CNS therapy\n   2. Previously treated brain metastases with progression of previous lesions or new lesions, but not requiring immediate local CNS therapy\n   3. At least one measurable untreated brain lesion ≥0.5 cm and \\\u003C3.0 cm in the longest axis\n   4. Prior SRS radiosurgery (must be completed within 7 days of study treatment initiation) is allowed as long as the previous treatment volume does not overlap with the current targets.\n5. Measurable disease per RECIST v1.1 criteria. For mCRPC patients, tumor response will be evaluated using RECIST version 1.1 (soft tissue) and PCWG-3 criteria (bone) and efficacy endpoints will also include radiographic progression-free survival (rPFS), PSA50 response and PSA progression\n6. Adequate bone marrow reserve, cardiac, liver, and renal function:\n\n   1. Absolute neutrophil count (ANC) ≥ 1,500\u002Fmm3\n   2. Platelet count ≥ 100,000\u002Fmm3\n   3. Hemoglobin ≥ 9 g\u002FdL\n   4. Bilirubin ≤ 1.5 × upper limit of normal (ULN) or direct bilirubin ≤ ULN for patients with total bilirubin levels \\>1.5 × ULN\n   5. Alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases are present)\n   6. INR ≤ 1.5 × ULN unless patient is receiving anticoagulant therapy and PT or aPTT is within therapeutic range of intended use of anticoagulants\n   7. Creatinine clearance ≥ 60 mL\u002Fmin (by Cockroft Gault formula).\n7. Female patients of child-bearing potential must have a negative serum pregnancy test and use at least 1 form of acceptable birth control method listed below as approved by the Investigator before initiating study treatment and for 3 months after the last dose of study drug.\n\n   1. Sterilization\n   2. Any hormonal contraceptives (non-CYP 3A4 inhibitors) associated with inhibition of ovulation\n   3. IUD (intrauterine device) or intrauterine hormone releasing system\n8. Male patients must be sterilized or use a form of barrier contraception, such as condoms with spermicide, during the study and for 3 months after the last dose of study drug.\n9. Life expectancy of ≥ 3 months.\n10. Ability to provide written informed consent.\n11. An Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.\n\nExclusion Criteria:\n\n1. Patients with symptomatic brain metastases requiring treatment and\u002For leptomeningeal disease\n2. Patients with a previous history of another malignancy (other than cured basal cell or squamous cell carcinoma of the skin or cured in-situ carcinoma) within 3 years of study entry.\n3. Patients with uncontrolled pleural effusions, pericardial effusion, or ascites that do not resolve.\n4. Patients with gastrointestinal tract disease causing the inability to take oral medication (e.g., swallowing difficulties, malabsorption syndromes, extensive small bowel resection \\[\\> 100cm\\], gastric bypass surgery).\n5. Pregnant or breast-feeding patients or any patient with child-bearing potential not using adequate contraception.\n6. Known human immunodeficiency virus, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (excluding cured HBV and\u002For cured HCV infection).\n7. Presence of any serious concomitant systemic disorders incompatible with the study in the opinion of the Investigator (e.g., uncontrolled congestive heart failure, active infection).\n8. Radiation therapy to \\> 30% of bone marrow within 3 months before study entry.\n9. Patients with clinically significant autoimmune disease, either currently present of present within 2 years, including a current requirement for systemic immunosuppressive therapy equivalent to \\> 10 mg\u002Fprednisone daily (local immunosuppressive therapy such as inhaled or topical corticosteroids is allowed).\n\n11\\. Patients with abnormal or clinically significant electrocardiogram (ECG) abnormality, including but not limited to a confirmed corrected QT interval using Fridericia's formula (QTcF) \\> 470 msec.\n\n12\\. Patient has received systemic anticancer therapy within 3 weeks or 5 half-lives, whichever is shorter.\n\n13\\. Patients must have recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline.\n\n14\\. Any of the following conditions (on-study testing is not required):\n\na. Known HIV-infected patients unless on effective anti-retroviral therapy with an undetectable viral load within 6 months and no opportunistic infection within the past 12 months, or b. Known or suspected hepatitis B if active infection (patients with chronic hepatitis B infection must have an undetectable HBV viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion), or c. Known or suspected hepatitis C infection that has not been treated and cured unless currently on treatment with an undetectable viral load.\n\n15\\. Administration of strong or moderate cytochrome (CYP) 3A4 inhibitors and inducers within 14 days or 5 half-lives (whichever is shorter) prior to the administration of study drug.","ALL","18 Years",{"count":19,"type":20},86,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.",[26,27],"Solid Tumor Malignancies","Brain Metastases From Solid Tumors",[29,30,31],"brain metastases","solid tumors","AO-252","RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":36},"2023-11-02",{"date":40,"type":20},"2028-01-27",{"name":42,"class":43},"A2A Pharmaceuticals Inc.","INDUSTRY",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":69,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100535595","phase-1-a-phase-11b-study-of-iam1363-in-her2-cancers-100535595","NCT06253871","A Phase 1\u002F1b Study of IAM1363 in HER2 Cancers","A Phase 1\u002F1b Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations","Key Inclusion Criteria:\n\n* Age ≥ 18 years\n* Have relapsed\u002Frefractory HER2-altered malignancy; for selected cohorts, prospective confirmation of HER2 alteration by central testing is required\n* Have progression of disease after the last systemic therapy, or be intolerant of last systemic therapy\n* Have radiographically measurable disease by RECIST v1.1 and\u002For RANO-BM\n* Eastern Cooperative Oncology Group (ECOG) performance score 0-1\n* Have adequate baseline hematologic, liver and renal function\n* Have left ventricular ejection fraction (LVEF) ≥ 50%\n* Able to swallow oral medication\n\nKey Exclusion Criteria:\n\n* Clinically significant cardiac disease\n* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: Participants with well-controlled HIV (e.g., CD4 \\>350\u002Fmm3 and undetectable viral load) are eligible\n* Current active liver disease including hepatitis A, hepatitis B , or hepatitis C\n* Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate absorption\n* Uncontrolled diabetes\n* History of solid organ transplantation\n* History of Grade ≥2 CNS hemorrhage, or any CNS hemorrhage within 28 days before C1D1\n* Prior history of non-infectious interstitial lung disease (ILD). (Exceptions: participants with prior grade 1 ILD that has completely resolved are eligible)\n* Participants requiring immediate local therapy for brain metastases",{"count":53,"type":20},383,[23],"This is a Phase 1\u002F1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.",[57,58,59,60,27,61,62,63,64,65,66,67,68],"HER2 Mutation-Related Tumors","HER2","HER2-positive Breast Cancer","HER2 + Breast Cancer","Brain Metastases From HER2 and Breast Cancer","CNS Metastases","HER2-Positive Solid Tumors","NSCLC (Non-small Cell Lung Cancer)","HER2-positive Bladder Cancer","HER2-positive Colorectal Cancer","HER2 + Gastric Cancer","HER2-positive Gastroesophageal Cancer",[70,71,72,73,74,75,76,77,78,79,58,29],"ERBB2 protein, human","Molecular Targeted Therapy","Genes, erbB-2","Receptor, ErbB-2 \u002F antagonists & inhibitors","Neoplasms \u002F drug therapy","HER2 positive","HER2 overexpressing","HER2 altered","Human epidermal growth factor receptor","ErbB Receptors","2026-06-02",{"date":82,"type":36},"2026-06-04",{"date":84,"type":36},"2024-03-25",{"date":86,"type":20},"2028-12",{"name":88,"class":43},"Iambic Therapeutics, Inc",53,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":115},"100610352","evaluating-biomarkers-of-cognitive-dysfunction-in-patients-with-cancer-100610352","NCT07226466","Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer","Inclusion Criteria:\n\n1. \\>= 18 years old\n2. Diagnosis of a primary brain tumor OR #3. Not both #2 and #3.\n3. Diagnosis of primary solid tumor and secondary involvement of the brain\n4. If the patient has brain metastases: fewer than 5 brain metastases (post-operative and definitive allowed), none \\> 1 cm in max diameter.\n5. Candidate for standard of care \u002F usual care (SOC) focused brain radiotherapy.\n6. No prior brain radiotherapy, including whole brain radiotherapy.\n7. Eastern Cooperative Oncology Group (ECOG) functional score 0 or 1.\n8. Estimated life expectancy post-treatment of \\> 2 years.\n\nExclusion Criteria:\n\n1. Diagnosis of neurodegenerative disease (Alzheimer's disease, Parkinson's disease).\n2. Diagnosis of memory disorder pre-treatment.\n3. Leptomeningeal disease or disease involving either hippocampus.",{"count":97,"type":20},40,"OBSERVATIONAL","This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.",[101,27,102,103],"Brain Tumor Adult","Brain Tumor, Primary","Brain Tumor","NOT_YET_RECRUITING","2026-05-20",{"date":107,"type":36},"2026-05-22",{"date":109,"type":20},"2026-07-01",{"date":111,"type":20},"2028-10-31",{"name":113,"class":114},"University of California, San Francisco","OTHER",1,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":126,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":115},"100634638","phase-2-comparison-of-the-therapeutic-effects-of-methylprednisolone-and-dexamethasone-on-peritumoral-edema-during-radiotherapy-for-brain-metastases-100634638","NCT07542288","Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:","Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:An Adaptive Phase II\u002FIII Seamless Prospective Clinical Study","Inclusion Criteria:\n\n* 1\\. 18 ≤ age ≤ 75 years old, gender not limited, generally acceptable, 40 ≤ KPS ≤ 80 points, the main reason for the patient's limited functional status is related neurological symptoms caused by edema of brain metastases; 2. Confirmed by cranial MRI or CT imaging, there is at least one brain metastasis with cerebral edema or neurological symptoms. All patients are scheduled to undergo WBRT (30 Gy\u002F10f or 20 Gy\u002F5f) or SBRT (20-40 Gy\u002F1-6f, with ≤ 5 brain metastases and a maximum diameter of ≤ 5cm per lesion); 3. Expected survival of ≥ 3 months; 4. Having sufficient cognitive and understanding abilities, able to cooperate with scale assessments, and able to sign a written informed consent form (ICF); 5. Baseline neurological symptoms are stable (no need for emergency surgical decompression), and if surgery\u002Fradiotherapy has been performed, the following conditions must be met: postoperative\u002Fradiotherapy interval ≥ 4 weeks; 6. Baseline blood glucose\u002Fmetabolism is controllable (e.g., HbA1c ≤ 8.0% in diabetes patients;If HbA1c is high, endocrinology evaluation is required and written permission for enrollment is granted.\n\nExclusion Criteria:\n\n* 1\\. Immediate surgical decompression is required, or there may be progressive cerebral herniation, intracranial pressure crisis, or life-threatening intracranial space occupying lesions present; 2. Has received systemic corticosteroid treatment within 7 days prior to the start of the study medication (such as due to the treatment of systemic lupus erythematosus, bronchial asthma, etc.); 3. Recent cranial surgery or radiation therapy (\\\u003C4 weeks); 4. Individuals with contraindications to glucocorticoids or severe immunosuppression; 5. Suffering from serious basic diseases such as uncontrolled hypertension and diabetes (HbA1c\\>8%), untreated mental illness, active gastric ulcer, heart failure (NYHA III-IV grade), etc; 6. Pregnant\u002Flactating women; 7. Unable to complete the primary assessment scale (severe cognitive\u002Fbehavioral impairment) or unable to sustain Follow up period (e.g. no fixed address, difficult to ensure follow-up); 8. Participated in other intervention therapy trials within the past 4 weeks (which may affect the evaluation results), or is currently receiving drugs that may have serious drug interactions with the investigational drug; 9. Other serious systemic diseases or unsuitability.","75 Years",{"count":125,"type":20},400,[127,128],"PHASE2","PHASE3","This study is a multicenter, open label, randomized controlled, adaptive phase II\u002FIII seamless design clinical trial aimed at comparing the efficacy and safety of methylprednisolone (MP) and dexamethasone (DEX) in the treatment of peritumoral edema in patients with brain metastases during radiotherapy. The research plan includes brain metastasis patients aged 18-75 years, with KPS scores of 40-80, who plan to undergo whole brain radiotherapy or stereotactic radiotherapy. They will be randomly divided into MP group (40-60 mg\u002Fday) or DEX group (8-12 mg\u002Fday) in a 1:1 ratio, and medication will be continued until the end of radiotherapy, followed by gradual reduction and cessation within one week. The study is divided into two stages: the first stage (stage II exploration) includes 120 cases to preliminarily evaluate the efficacy and safety, and provide a basis for re estimating the sample size in the second stage; The second stage (Phase III confirmation) will expand the sample size based on the results after analysis during the transition period, with a total sample size of no more than 400 cases. The primary endpoint was the change in KPS score and the incidence of grade ≥ 2 hormone related adverse reactions within one week after radiotherapy. Secondary endpoints include cerebral edema index, cognitive function, quality of life, radiotherapy interruption rate, neurotoxicity, survival, and serum biomarkers (IL-6, S100B). The study is supervised by an independent data security monitoring committee and uses statistical methods such as stratified block randomization and mixed effects models to ensure the scientific and ethical compliance of the data. This study is expected to provide high-level evidence-based basis for hormone selection during the perioperative radiotherapy period for patients with brain metastases, and optimize clinical practice.",[27],[132,133,134,135,136,137],"Brain metastases","Methylprednisolone","Dexamethasone","Peritumoral edema","Karnofsky performance status score","Biomarkers","2026-04-14",{"date":140,"type":36},"2026-04-21",{"date":142,"type":20},"2026-04-15",{"date":144,"type":20},"2028-06-30",{"name":146,"class":114},"The Second Affiliated Hospital of Hainan Medical University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":4},"100631845","phase-2-smart-trial-cognitive-sparing-brain-radiotherapy-for-multiple-brain-metastases-100631845","NCT07505979","SMART Trial: Cognitive Sparing Brain Radiotherapy for Multiple Brain Metastases","Stereotactic RadioSurgery Versus Memantine Plus Cognitive Sparing or Hippocampal Avoidance Whole Brain RadioTherapy for Multiple Brain Metastases (SMART): A Phase II Randomized Trial","Inclusion Criteria:\n\n1. Patients with a histologic diagnosis of non-hematopoietic malignancy and radiographic evidence of brain metastases\n2. Patients with brain metastasis outside a 5-mm margin around either hippocampus or corpus callosum on gadolinium contrast-enhanced MRI obtained within 30 days prior to registration\n3. Patients with 6 or more active or progressive brain metastases that have not been treated by radiotherapy or radiosurgery\n4. No evidence of diffuse leptomeningeal metastasis on gadolinium-enhanced MRI within 30 days prior registration\n5. Age ≥ 18 years\n6. Karnofsky Performance Status ≥ 60%\n7. Life expectancy ≥ 6 months.\n8. Women of childbearing potential and male participants must practice adequate contraception\n9. Patients must be able to comply with the study protocol and follow-up schedules and provide study-specific informed consent\n\nExclusion Criteria:\n\n1. Prior radiotherapy to brain or radiosurgery to \\> 5 intracranial metastatic lesion(s)\n2. Clinical diagnosis of symptomatic leptomeningeal metastsases\n3. Contraindication to MR imaging such as implanted metal devices or foreign bodies, severe claustrophobia\n4. Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:\n\n   1. Uncontrolled active infection requiring intravenous antibiotics at the time of registration\n   2. Transmural myocardial infarction ≤ 6 months prior to registration\n   3. Unstable angina or congestive heart failure requiring hospitalization ≤ 6 months prior to registration\n   4. Life-threatening uncontrolled clinically significant cardiac arrhythmias\n   5. Hepatic insufficiency resulting in clinical jaundice and\u002For coagulation defects\n   6. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\n   7. Uncontrolled psychiatric disorder\n5. Will receive any other investigation agent or chemotherapy during cranial radiotherapy or radiosurgery\n6. Current use of Memantine HCL or Allergy to Memantine HCL\n7. Women of childbearing potential and male participants who are sexually active and not willing\u002Fable to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic\n8. Pregnant or breast-feeding women",{"count":155,"type":20},90,[127],"The goal of this phase II randomized trial is to determine if Stereotactic Radiosurgery (SRS) or Cognitive Sparing WBRT (CS-WBRT) better preserves neurocognitive function than standard Hippocampal Avoidance WBRT (HA-WBRT) in patients with multiple brain metastases ( $\\\\ge6$ lesions).\n\nThe main questions it aims to answer are:\n\n* Which treatment best preserves cognitive function (memory and executive tasks) at 6 months post-intervention?\n* Can sparing the left hippocampus and corpus callosum (CS-WBRT) or using focal SRS reduce cognitive decline compared to bilateral sparing? Comparison Groups\n\nResearchers will compare three arms to evaluate their impact on cognition and disease control:\n\n* Arm A (SRS): Focal high-dose radiation (15-20 Gy in 1 fraction) to intracranial lesions.\n* Arm B (CS-WBRT): Whole-brain radiation (30 Gy in 10 fractions) sparing the left hippocampus and corpus callosum plus Memantine.\n* Arm C (HA-WBRT): Whole-brain radiation (30 Gy in 10 fractions) with bilateral hippocampal avoidance plus Memantine.\n\nParticipant Tasks\n\nParticipants will:\n\n* Complete neurocognitive and neuropsychological tests (HVLT-R, TMT, COWAT, CANTAB) at baseline and follow-up.\n* Undergo contrast-enhanced brain MRI for planning and tracking tumor progression.\n* Take Memantine HCL daily for 24 weeks if assigned to the WBRT arms (B or C).\n* Provide blood samples for biomarker and genetic analysis (e.g., APOE, Tau).\n* Undergo olfactory function testing and complete quality-of-life questionnaires.",[27],[132,160,161,162],"Cognitive Preservation","Hippocampal Avoidance Whole Brain Radiotherapy","Stereotactic Radiosurgery","2026-04-06",{"date":165,"type":36},"2026-04-13",{"date":167,"type":20},"2026-04",{"date":169,"type":20},"2031-04",{"name":171,"class":114},"National Taiwan University Hospital"]